Project Huskies Management Presentation May 2026 THIS PRESENTATION MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION CONCERNING THE COMPANY (AS DEFINED HEREIN) AND ITS SUBSIDIARIES. BY ACCEPTING THIS PRESENTATION, THE RECIPIEN

SUBJECT TO EXECUTED NDA | CONFIDENTIAL Con | fid CO en NT tia AINS l |

CoNON ntain- sP No UBLIC n-PuINFORMAT blic InformaIO tioN n Exhibit 99.1 Project Huskies Management Presentation May 2026 THIS PRESENTATION MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION CONCERNING THE COMPANY (AS DEFINED HEREIN) AND ITS SUBSIDIARIES.

BY ACCEPTING THIS PRESENTATION, THE RECIPIENT AGREES TO USE ANY SUCH INFORMATION IN ACCORDANCE WITH ITS COMPLIANCE POLICIES, CONTRACTUAL OBLIGATIONS AND APPLICABLE LAW, INCLUDING UNITED STATES FEDERAL AND STATE SECURITIES LAWS. Ducera 2026

Confidential & Proprietary Information | Provided Pursuant to Executed NDA Ducera

SU SUBJ BJECT ECT T TO O EX EXECU ECUT TED ED ND NDA A || CO CO CONFID

NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -P P PU U UBLIC BLIC BLIC INFORMAT INFORMAT INFORMATIO IO ION N N Disclaimer Presentation This presentation and the information contained herein is confidential and

proprietary to Accendra Health, Inc. and its subsidiaries ("Accendra Health" or the "Company") and is being provided to you subject to certain confidentiality obligations to which you are a party (including any

confidentiality obligations pursuant to agreements that govern the Company's indebtedness that you are a party to) (collectively, the "Confidentiality Agreements"). By accepting and/or viewing the contents of this presentation, you

expressly agree to maintain the confidentiality of this presentation (including its existence) in accordance with the terms of the applicable Confidentiality Agreements and you further agree to the special notice set forth on the cover page hereof.

If you are not willing to accept this presentation on the terms set forth herein and the special notice on the cover page hereof, you must return the presentation immediately without making any copies or extracts or using or viewing the information

contained herein in any manner. If you are not the intended recipient of this presentation, you may not disclose or use the information in this presentation in any way. This presentation is being shared with you for informational purposes only and

does not represent any commitment, promise or legal obligation, nor is it intended as an offer or solicitation with respect to the purchase or sale of any security. This presentation does not constitute an offer or commitment to lend, syndicate or

arrange a financing, underwrite or purchase or act as an agent or advisor or in any other capacity with respect to any transaction. This presentation does not constitute and should not be considered as any form of legal, financial, accounting,

investment or tax advice. This document is not, and under no circumstances is to be construed as, a prospectus, a public offering or an offering memorandum as defined under any applicable securities laws. None of Accendra Health, its affiliates,

officers, directors, employees, professional advisors, agents or other representatives (collectively with Accendra Health, the "Company Representatives") make any representation or warranty, express or implied, as to, and no reliance

should be placed on, the fairness, accuracy, completeness or correctness of any of the information or opinions contained in this presentation. Furthermore, none of the Company Representatives shall have liability for damages of any kind, including,

without limitation: direct, special, indirect or consequential damages that may result from the use of or reliance upon this presentation. Accendra Health has no obligation to pursue any course of business outlined in this presentation or any

related documentation, and Accendra Health's strategy and possible future developments, products and/or directions are all subject to change and may be changed by Accendra Health at any time for any reason without notice. Forward-Looking

Statements This presentation contains certain "forward-looking" statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the

statements in this presentation regarding our future prospects and performance, including our expectations with respect to our financial performance and financial results (and other financial projections), our expectations regarding the performance

of our business following the completion of the sale of the Products & Healthcare Service business, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the

performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from

those projected or contemplated in the forward-looking statements. Investors should refer to Accendra Health's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section

captioned "Item 1A. Risk Factors," as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the

Company's actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, Accendra Health can give no assurance that any forward-looking statements

will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Accendra Health specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future

developments or otherwise. Financial Information Certain financial measures included herein are not prepared in accordance with U.S. GAAP, including Adjusted EBITDA, Adjusted EBITDA-Capex, Levered Free Cash Flow, Unlevered Free Cash Flow, Normalized

Unlevered Free Cash Flow, Interest Coverage Ratio, Weighted Average Life, Implied Net 1L Leverage, and Implied Net Leverage, and use of such terms varies from others in the same industry. Management uses these non-GAAP financial measures internally

to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Non-GAAP financial measures should not be considered as alternatives to measures derived in accordance with

U.S. GAAP. Non-GAAP financial measures have important limitations as analytical tools and you should not consider them in isolation or as substitutes for results as reported in accordance with U.S. GAAP. Reconciliations of projected or targeted

non-GAAP financial measures are not provided herein because such GAAP financial measures are not available on a forward-looking basis and such reconciliations could not be derived without unreasonable effort. We present certain potential add-backs

as an adjustment to Adjusted EBITDA because we expect them to be a permitted add-back pursuant to agreements that govern or will govern our indebtedness. These potential add-backs are based on assumptions and estimates that could prove to be

incorrect, and accordingly should not be viewed as a projection of future performance. Unless otherwise indicated, projected and forward-looking financial information and operating data presented herein reflect Accendra Health on a post-divestiture

basis and exclude the results of operations of the Products & Healthcare Services business ("P&HS"). 2026 Confidential & Proprietary to Accendra Health, Inc. p. p. 2 2 Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Table of Contents I. Accendra Health Overview II. Recent

Financial Performance III. Key Investment Highlights IV. Capital Structure Optimization V. Appendix p. 3 p. 3 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera

SU SUBJ BJECT ECT T TO O EX EXECU ECUT TED ED ND NDA A || CO CONFID

NFIDEN ENT TIAL IAL || CO CONT NTAINS AINS NON NON- -P PU UBLIC BLIC INFORMAT INFORMATIO ION N I. Accendra Health Overview p. p. 4 4 Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Introducing Accendra Health ~2,500 ~$2.8B ~2.9 million Commercial

Payor FY25A Revenue Active Patients Contracts Business Overview FY25A Revenue by Disease State Pure-Play Patient Direct Leader: Leading U.S. 28% 27% 16% 8% 7% 4% 10% provider of in-home medical equipment, supplies and services following the

P&HS divestiture 0% 20% 40% 60% 80% 100% Scaled Chronic Focused Portfolio: ~$2.8B Diabetes Sleep Respiratory Ostomy Wound Care Urology Other FY25A net revenue across diabetes, sleep therapy, respiratory and complementary chronic

categories FY25A Revenue by Payor National Footprint and Operational Scale: 250+ locations, regional distribution centers and national pharmacy enable high quality service at scale 18% 1% 81% Broad Payor Access and Reach: ~85% of

U.S. (1) ~6-7% exposure to CBP population accessible through payor 0% 20% 40% 60% 80% 100% (1) Commercial Medicare Fee-for-Service Medicaid relationships p. 5 p. 5 2026 Confidential & Proprietary to Accendra Health, Inc. (1) DME Medicare

categories are not impacted by the CMS ruling issued on November 28, 2025; Ducera however, ~6-7% of the total payor mix may be affected

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Accendra Health's Corporate History and Evolution

Disciplined expansion and portfolio optimization have culminated in a pure-play home-based care platform Enhance Capabilities to Serve Pivot to Home-Based Chronic Condition Patients Patient Care Dec 2025: Products & Healthcare Aug 2017:

Acquisition of Byram, a Services (P&HS) segment acquired by distribution business focused on Platinum Equity chronic disease 2017 2019 2021 2023 2025 Accelerate Growth in Home Care Mar 2022: Acquisition of Apria, a provider of durable home

health equipment p. 6 p. 6 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Accendra Health is a Key Partner in the Patient Journey Patients

at Home Physicians & Hospital Systems Chronic Patient Focus: Serves patients Accendra Health's solutions support high with ongoing needs for equipment and quality healthcare beyond the hospital supplies - Accendra

Health's Solutions Accelerate Discharge Velocity: Speed A vital link - Concentrated Chronic Disease Focus: up patient transition to home-based between patients, Post-separation, diabetes represents care, directly mitigating readmission

providers, and ~28% of FY25A Revenue, more than penalties payors, delivering doubling its prior relative weight solutions to improve lives Differentiated portfolio of capabilities to Payors across the serve patients at home spectrum of

chronic and acute Accendra Health partners with Payors to care Pure-Play Focus: Allows 100% of provide members with reliable access to home healthcare capital allocation to support the "lifelong treatment journey"

for 37M+ U.S. Diabetics and 85M+ - Preferred National Footprint: Sleep Apnea sufferers Anchored by a recently activated (Sept 2025) national Preferred Provider Agreement with Optum Health p. 7 p. 7 2026 Confidential & Proprietary to

Accendra Health, Inc. Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Accendra Health's Breadth and Scale Accendra Health is a

scaled, pure-play leader in home health Patient Reach Nationwide, Rapid Fulfillment Physical Infrastructure ~85% U.S. ~23,500 home deliveries >250 Population Reach each day Locations Each year, the company supports Ability to fulfill orders

rapidly, as Nationwide physical location ~2.9M patients with essential fast as 4 hours, at scale. Network network, including full-service medical supplies and equipment breadth optimizes shipping pharmacy capabilities. ~2,500 delivered directly to

their homes distance and in-home delivery payor contracts with experience speed, supporting timely patient operating under managed care and discharge capitated reimbursement models p. 8 p. 8 2026 Confidential & Proprietary to Accendra

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Accendra Health's Vision and Strategic Mission Making

healthcare more accessible and personalized, supporting patients' quality of life through nationwide clinical support Vision Mission Approach Large Physician & Clinical Network Reimagine the Future of Improve the Quality of Life Improve Quality

Home-Based Care for our Patients at Home Patient Reach of Care at Home Innovative At- Home Solutions p. 9 p. 9 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera Source: Company Materials

SU SUBJ BJECT ECT T TO O EX EXECU ECUT TED ED ND NDA A || CO CONFID

NFIDEN ENT TIAL IAL || CO CONT NTAINS AINS NON NON- -P PU UBLIC BLIC INFORMAT INFORMATIO ION N II. Recent Financial Performance p. p. 10 10 Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Accendra Health's FY2025 Financial Snapshot Accendra

Health's revenue is diversified and strategically positioned across home-based care categories, supporting stability ~$2.8B FY25A revenue Revenue by Disease State (FY25A) Other Strategic position in key categories 10% Urology

Diabetes category is primarily 4% Diabetes 28% comprised of Type 1 and insulin- Wound Care 7% dependent Type 2 patients Leading revenue cycle management 8% Ostomy Breadth of categories helps stabilize revenues and reimbursement

shifts 16% 27% Respiratory Enhancements to the Sleep Journey Sleep Program that drive higher recurring revenue p. 11 p. 11 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N A Favorable Payor Mix that Commercially-weighted

payor access supports durable demand 290M Covered lives Payor Mix Accendra Health Access to ~85% of U.S. population Medicaid partners with Medicare 1% (1) Fee-for-Service payors covering Growing Medicare Advantage ~6-7% population

exposure 18% (1) to CBP Majority of payor partnerships are 290M evergreen Lives Rated Best Overall Diabetes Supplier (2) 2020-2024 81% Net Promoter Scores of 2-3x Commercial (3) healthcare benchmarks p. 12 p. 12 2026

Confidential & Proprietary to Accendra Health, Inc. (1) DME Medicare categories are not impacted by the CMS ruling issued on November 28, 2025; Ducera however, ~6-7% of the total payor mix may be affected (2) Awarded by Verywell Health,

which discontinued its award program after 2024 (3) Reflects benchmark per NPSpack 2025 Benchmark Guide

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Establishes Accendra Health as a Market Leader in

Home-Based Care Accendra Health's platform is positioned to benefit from secular trends in home-based care ($ in millions) Accendra Health has built a strong growth $3,000 Strong organic growth platform that is at the center of where

healthcare post-M&A is trending $2,500 Doubled down on the belief in the home-based $2,000 care business with the addition of Apria and Byram $1,500 Track record of strong growth throughout our path $1,000 A strong player

in the future of home-based care Faster recovery $500 Safer Preferred by patients, providers, and payors $- (1) 2017 2021 2025 p. 13 p. 13 2026 Confidential & Proprietary to Accendra Health, Inc. (1) Reflects the

latest reported LTM financials (FY21) for Apria prior to its acquisition by Accendra Ducera Health in March 2022 Revenue

SU SUBJ BJECT ECT T TO O EX EXECU ECUT TED ED ND NDA A || CO CONFID

NFIDEN ENT TIAL IAL || CO CONT NTAINS AINS NON NON- -P PU UBLIC BLIC INFORMAT INFORMATIO ION N III. Key Investment Highlights p. p. 14 14 Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Key Investment Highlights Accendra Health demonstrates clear

credit strengths that support its position as a leading, scaled platform in the home-based care industry 1 Experienced Management with Proven Track Record 2 Favorable Industry Tailwinds 3 Accendra Health's Capabilities Versus Industry

Landscape 4 Resilient, High-Margin Home-Based Care Business Diversified Earnings Profile and Cash Flow Generation 5 p. 15 p. 15 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera

P SU SU RIBJ BJ VAT ECT ECT E SI T TD O O E EX EX INFORMAT ECU ECUT TED

ED ND ND ION A A ||| CO CO CONFID NFID NFIDEN EN ENT T TIAL IAL IAL ||| CO CO CONT NT NTAINS AINS AINS NON NON NON- - -PU P PU UBLI BLIC BLIC C INFORMAT INFORMAT INFORMATIO IO ION N N Highly Experienced Management Team with 1 Proven Track Record of

Success Accendra Health's management team has successfully navigated various market cycles and established an actionable go-forward strategy Years of Experience Previous Experience Accomplishments ED PESICKA Successful rebrand and

launch of the Accendra President & 25+ Health name following the divestiture of the P&HS Chief Executive Officer business, accelerating the transformation to a pure-play home-based care business JON LEON EVP & 25+ Fully

integrated Apria and Byram Health Chief Financial Officer acquisitions Improved shipping accuracy to ~99.9% PERRY BERNOCCHI EVP & 25+ Successfully navigated shifting demands of Chief Operating Officer COVID-19 pandemic

Continued delivery of consistent, high-quality HEATH GALLOWAY patient services, establishing Accendra Health as EVP, General Counsel, & 20+ an industry leader Corporate Secretary WILLIAM PARRISH VP of Strategy, Corporate 15+ Development,

Investor Relations p. 16 p. 16 2026 Confidential & Proprietary to Accendra Health, Inc. Ducera